Healthcare - Biotechnology - NASDAQ - US
$ 12.03
-13.6 %
$ 637 M
Market Cap
-5.78
P/E
CASH FLOW STATEMENT
-81.1 M
OPERATING CASH FLOW
106 M
INVESTING CASH FLOW
53 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Stoke Therapeutics, Inc.
| Net Income | -105 M |
| Depreciation & Amortization | 2.47 M |
| Capital Expenditures | -1.62 M |
| Stock-Based Compensation | 25.3 M |
| Change in Working Capital | -6.03 M |
| Others | -886 K |
| Free Cash Flow | -82.7 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (104.7) | (101.1) | (85.8) | (52.2) | (32.3) | (12.5) | (5.6) |
| Depreciation & Amortization | 2.5 | 1.5 | 1.0 | 0.9 | 0.5 | 0.2 | 0.1 |
| Deferred Income Tax | 0 | 0 | 0.2 | 3 K | 0 | 0 | 0 |
| Stock Based Compensation | 25.3 | 22.9 | 16.4 | 5.8 | 1.9 | 0.2 | 26 K |
| Other Operating Activities | 1.9 | 1.8 | 1.3 | 1.0 | 3 K | 10 K | 4 K |
| Change in Working Capital | (6.0) | 43.0 | 46 K | 2.3 | (1.1) | 1.1 | 31 K |
| Cash From Operations | (81.1) | (31.9) | (66.9) | (42.2) | (31.1) | (11.0) | (5.4) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (1.6) | (4.0) | (1.2) | (1.1) | (1.6) | (0.9) | (0.1) |
| Other Items | 107.6 | (41.9) | (75.2) | 0 | 1 K | 10 K | 0 |
| Cash From Investing Activities | 105.9 | (45.9) | (76.4) | (1.1) | (1.6) | (0.9) | (0.1) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.9 | 1.1 | 1.3 | 2.7 | (2.1) | 115.6 | 6.0 |
| Cash From Financing Activities | 53.0 | 46.4 | 1.3 | 108.1 | 149.8 | 115.6 | 6.0 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 77.9 | (31.3) | (142.0) | 64.8 | 117.1 | 103.8 | 0.5 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (82.7) | (35.8) | (68.1) | (43.3) | (32.7) | (11.9) | (5.5) |